Loading...
•
Mar 31, 2021
Adicet Bio Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Adicet Bio reported financial results for the first quarter ended March 31, 2021. The company successfully raised $143.8 million in net proceeds and initiated the Phase 1 trial of ADI-001 for NHL treatment.
Initiated Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma (NHL).
Successfully raised $143.8 million in net proceeds through a public offering and concurrent private placement to advance a pipeline of CAR gamma-delta T cell therapies.
Appointed Dr. Blake Aftab as Vice President of Research.
Appointed Andrew Sinclair, Ph.D., to the Company’s Board of Directors.